285 related articles for article (PubMed ID: 34753780)
1. The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.
Lee JK; Hazar-Rethinam M; Decker B; Gjoerup O; Madison RW; Lieber DS; Chung JH; Schrock AB; Creeden J; Venstrom J; Alexander B; Oxnard GR
Clin Cancer Res; 2022 Feb; 28(4):728-737. PubMed ID: 34753780
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
Mondaca S; Lebow ES; Namakydoust A; Razavi P; Reis-Filho JS; Shen R; Offin M; Tu HY; Murciano-Goroff Y; Xu C; Makhnin A; Martinez A; Pavlakis N; Clarke S; Itchins M; Lee A; Rimner A; Gomez D; Rocco G; Chaft JE; Riely GJ; Rudin CM; Jones DR; Li M; Shaffer T; Hosseini SA; Bertucci C; Lim LP; Drilon A; Berger MF; Benayed R; Arcila ME; Isbell JM; Li BT
Lung Cancer; 2021 Sep; 159():66-73. PubMed ID: 34311346
[TBL] [Abstract][Full Text] [Related]
3. Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
Mack PC; Keller-Evans RB; Li G; Lofgren KT; Schrock AB; Trabucco SE; Allen JM; Tolba K; Oxnard GR; Huang RSP
Oncologist; 2024 Feb; ():. PubMed ID: 38401173
[TBL] [Abstract][Full Text] [Related]
4. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR
Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T; Kenmotsu H; Hazama D; Teraoka S; Kobe H; Azuma K; Yamaguchi T; Masuda T; Yokoyama T; Otsubo K; Haratani K; Hayakawa D; Oki M; Takemoto S; Ozaki T; Akashi Y; Hata A; Hashimoto H; Yamamoto N; Nakagawa K
Cancer Med; 2023 Dec; 12(23):21097-21110. PubMed ID: 37948122
[TBL] [Abstract][Full Text] [Related]
7. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
8. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
9. Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.
Xie J; Yao W; Chen L; Zhu W; Liu Q; Geng G; Fang J; Zhao Y; Xiao L; Huang Z; Zhao J
BMC Cancer; 2023 Mar; 23(1):294. PubMed ID: 37004022
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression.
Aldea M; Hendriks L; Mezquita L; Jovelet C; Planchard D; Auclin E; Remon J; Howarth K; Benitez JC; Gazzah A; Lavaud P; Naltet C; Lacroix L; de Kievit F; Morris C; Green E; Ngo-Camus M; Rouleau E; Massard C; Caramella C; Friboulet L; Besse B
J Thorac Oncol; 2020 Mar; 15(3):383-391. PubMed ID: 31843682
[TBL] [Abstract][Full Text] [Related]
11. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
14. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
15. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
16. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with
Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D
Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654
[TBL] [Abstract][Full Text] [Related]
17. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
[TBL] [Abstract][Full Text] [Related]
18. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
19. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
[TBL] [Abstract][Full Text] [Related]
20. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
